Jazz Pharmaceuticals’ efforts to get its cannabidiol therapy approved in Japan have hit a snag after a Phase III trial in Japan evaluating the therapy failed to meet its primary endpoint.
The Phase III study evaluated the cannabidiol oral solution as an adjunct treatment for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) or tuberous sclerosis complex (TSC) in paediatric patients. The study failed to achieve its primary endpoint of a pre-specified percentage change in indication-associated seizure frequency during the 16-week treatment period compared to baseline.
Jazz’s cannabis-based cannabidiol therapy is marketed as Epidiolex in the US and Epidyolex in the European Union. The company added the therapy to its portfolio as part of the 2021 acquisition of GW Pharmaceuticals. The US Food and Drug Administration (FDA) has approved the therapy for treating seizures associated with paediatric patients with three rare epileptic disorders, namely Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Epidiolex/Epidyolex is a high revenue-generating drug for Jazz. It raked in approximately $845.5m in sales last year, as per Jazz’s financials. GlobalData expects the therapy sales to continue their upward trajectory and generate $1.3bn by 2030.
GlobalData is the parent company of Clinical Trials Arena.
Despite the Phase III setback, Jazz plans to continue the therapy’s development in Japan. The company’s executive vice president Rob Iannone said: "We are confident in the overall clinical profile of Epidyolex, which has been established in five Phase III clinical trials in more than 900 patients.
“We believe the totality of the Epidyolex global data, including the findings from this trial, supports the advancement of the program in Japan. We are continuing to collect data on Japanese patients and plan to engage with regulatory authorities in Japan regarding a potential new drug application (JNDA).”
The open-label Phase III trial enrolled 62 paediatric patients between the ages of 1 and 18 years, who suffer from seizures due to either LGS, DS, or TSC. Jazz noted that while the primary endpoint was not met, numeric improvements were observed in the primary and several secondary endpoints.
